home / stock / bngo / bngo news

BNGO News and Press, Bionano Genomics Inc.

Stock Information
Company Name: Bionano Genomics Inc.
Stock Symbol: BNGO
Market: NASDAQ
Website: bionanogenomics.com
Menu
BNGO BNGO Quote BNGO Short BNGO News BNGO Articles BNGO Message Board
Get BNGO Alerts

News, Short Squeeze, Breakout and More Instantly...
BNGO - Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026

SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2025 and to high...
BNGO - Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale

SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and high-volume cytogenetics and molecular pathology laboratories in the United Stat...

BNGO - 10 Presentations on Day 3 of Bionano Symposium 2026 Showcase OGM's Utility in Unraveling the Complex Puzzles of Constitutional Genetic Disorders

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 3 of Bionano Symposium 2026, entitled  OGM Making its Mark in Constitutional Genetic Disorders . Presentations highlighted how these conditions, which include developmental ...

BNGO - 11 Presentations on Day 2 of Bionano Symposium 2026 Showcase Expanding Impact of Optical Genome Mapping Across Oncology and Cell & Gene Therapy

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 2 of Bionano Symposium 2026, which focused on New Frontiers in Oncology and Bioprocessing Applications with Optical Genome Mapping (OGM). The session revealed how OGM can offer a...
BNGO - 9 Presentations Kick Off Day 1 of the Bionano Symposium 2026 Covering Advances in Optical Genome Mapping for Hematologic Malignancies

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 1 of the Bionano Symposium 2026 entitled Advancements in Hematologic Malignancies with Optical Genome Mapping (OGM). Hematologic malignancies are cancers of the blood and lymph s...

BNGO - Bionano Announces Bionano Symposium 2026: Global Experts Showcase Advances and Innovation in Optical Genome Mapping

SAN DIEGO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced Bionano Symposium 2026, the premier global event for the optical genome mapping (OGM) community. This virtual symposium provides a unique platform for researchers to present cutting-edge findings an...

BNGO - Bionano Announces Publication from Sanford Burnham Prebys Medical Discovery Institute Describing use of OGM to Detect Genomic Alterations Introduced by Gene Editing Technologies

SAN DIEGO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced a peer-reviewed study published in Molecular Therapy - Methods & Clinical Development , describing the application of optical genome mapping (OGM) to detect genomic alterations introduced by differen...
BNGO - Bionano Reports Preliminary Fourth Quarter and Full-Year 2025 Results

SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today reported certain unaudited preliminary financial results and commercial highlights for the fourth quarter and fiscal year ended December 31, 2025. “2025 was a pivotal year for Bionano. We transformed...

BNGO - Bionano Recaps Advances in Optical Genome Mapping Showcased at AMP 2025

SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) participated in the Association for Molecular Pathology (AMP) Annual Meeting, held November 11-15, 2025 in Boston, MA. Key presentations at the conference highlighted how optical genome mapping (OGM) can enhance the dete...

BNGO - Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), announced today that the clinical lab fee schedule (CLFS) for 2026...
Next 10